News / Biotech
Galecto Acquires Damora Therapeutics: A New Focus on Blood Cancer Treatments
Galecto, Inc. (NASDAQ: GLTO) has completed its acquisition of Damora Therapeutics, a privately held biotech firm specializing in treatments for mutant calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPNs). This strategic move, a...